FDA Approves New Gene Therapy for Hemophilia B: A Milestone in 2025

The U.S. Food and Drug Administration (FDA) today approved Hemgenix-Next, an adeno-associated virus (AAV) vector-based gene therapy for the treatment of adults with Hemophilia B. A One-Time Treatment Unlike current standard-of-care trea...